Update on the use of dutasteride in the management of benign prostatic hypertrophy.

Abstract

Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary tract infection, and acute urinary retention. Medical treatments of symptomatic BPH include; 1) the 5alpha-reductase inhibitors, 2) the alpha1-adrenergic antagonists, and 3) the combination of a 5alpha-reductase inhibitor and a alpha1-adrenergic antagonist. Selective alpha1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that alpha1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5alpha-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. The combination of a 5alpha-reductase inhibitor and a alpha1-adrenergic antagonist reduces the clinical progression of BPH over either class of drug alone.

• Authors: Joe Miller, Thomas H Tarter
• Journal: Clinical interventions in aging (Clin Interv Aging) Vol. 2 Issue 1 Pg. 99-104 ( 2007) ISSN: 1176-9092 [Print] New Zealand
• PMID: 18044081 (Publication Type: Journal Article, Review)

Chemical References

• Azasteroids
• Enzyme Inhibitors
• Dutasteride

Topics

• Azasteroids (adverse effects, chemistry, pharmacokinetics, therapeutic use)
• Dutasteride
• Enzyme Inhibitors (adverse effects, chemistry, pharmacokinetics, therapeutic use)
• Humans
• Male
• Prostatic Hyperplasia (drug therapy)
• Prostatic Neoplasms (drug therapy, prevention & control)
• Quality of Life
• Treatment Outcome